Education
About Us
Working with TipRanks
Follow Us
Zevra Therapeutics (ZVRA)
NASDAQ:ZVRA
ZVRA Stock Chart & Stats
$11.08
$0.38(4.61%)
At close: 4:00 PM EST
$11.08
$0.38(4.61%)
Day’s Range― - ―
52-Week Range$6.19 - $13.16
Previous CloseN/A
Volume189.47K
Average Volume (3M)2.44M
Market Cap
$568.09M
Enterprise Value$342.29M
Total Cash (Recent Filing)$47.71M
Total Debt (Recent Filing)$62.28M
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Nov 05, 2025EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.21
Shares Outstanding56,135,090
10 Day Avg. Volume2,552,948
30 Day Avg. Volume2,436,184
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.60
Enterprise Value/Revenue5.52
Enterprise Value/Gross Profit7.67
Enterprise Value/Ebitda-2.97
Forecast
1Y Price Target
$24.50Price Target Upside121.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
European Market ExpansionZevra filed a marketing authorization application with the European Medicines Agency for arimoclomol, marketed in the U.S. as Miplyffa, for the treatment of Niemann-Pick disease type C (NPC).
FDA ApprovalZevra received FDA approval of Miplyffa in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC).
Product Launch And Revenue GrowthMiplyffa continues to show strong early uptake, generating revenue of $21.5M and 129 patient enrollments in total.
Bears Say
Olpruva Commercial ChallengesDespite strong results for Miplyffa, ZVRA shares are down due to issues with Olpruva.
Slower Olpruva AdoptionAdoption of Olpruva has been slower due to the mature UCD market and strong patient satisfaction with existing treatments.
Zevra Therapeutics News
ZVRA FAQ
What was Zevra Therapeutics’s price range in the past 12 months?
Zevra Therapeutics lowest stock price was $6.19 and its highest was $13.16 in the past 12 months.
What is Zevra Therapeutics’s market cap?
Zevra Therapeutics’s market cap is $568.09M.
When is Zevra Therapeutics’s upcoming earnings report date?
Zevra Therapeutics’s upcoming earnings report date is Nov 05, 2025 which is in 6 days.
How were Zevra Therapeutics’s earnings last quarter?
Zevra Therapeutics released its earnings results on Aug 12, 2025. The company reported $1.21 earnings per share for the quarter, missing the consensus estimate of $2.264 by -$1.054.
Is Zevra Therapeutics overvalued?
According to Wall Street analysts Zevra Therapeutics’s price is currently Undervalued.
Does Zevra Therapeutics pay dividends?
Zevra Therapeutics does not currently pay dividends.
What is Zevra Therapeutics’s EPS estimate?
Zevra Therapeutics’s EPS estimate is -0.03.
How many shares outstanding does Zevra Therapeutics have?
Zevra Therapeutics has 56,135,090 shares outstanding.
What happened to Zevra Therapeutics’s price movement after its last earnings report?
Zevra Therapeutics reported an EPS of $1.21 in its last earnings report, missing expectations of $2.264. Following the earnings report the stock price went down -19.813%.
Which hedge fund is a major shareholder of Zevra Therapeutics?
Currently, no hedge funds are holding shares in ZVRA
Zevra Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.50 (121.12% Upside)
$24.50 (121.12% Upside)
Hedge Fund Trend
Decreased
By 51.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $228.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 25.1%
Last 30 Days ▲ 25.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
31.33%
12-Months-Change
Fundamentals
Return on Equity
3.53%
Trailing 12-Months
Asset Growth
77.47%
Trailing 12-Months
Company Description
Zevra Therapeutics
Zevra Therapeutics (ZVRA) is a biopharmaceutical company focused on developing innovative therapies for patients with rare and complex diseases. The company specializes in advancing novel treatments that target unmet medical needs, leveraging its proprietary drug development platforms. Zevra's core products include therapies aimed at neurological and metabolic disorders, with a strong emphasis on delivering effective solutions for conditions that currently lack adequate treatment options.
ZVRA Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Zevra demonstrated strong financial performance with significant revenue growth from MIPLYFFA and strategic financial maneuvers, including the sale of PRV. The expansion efforts in Europe and increased coverage and retention rates for MIPLYFFA indicate positive momentum. However, challenges remain with the slow adoption of OLPRUVA and increased SG&A expenses. The limited progress in the DiSCOVER trial enrollment also poses a concern. Overall, the positive aspects outweigh the negatives, but challenges still need to be addressed.View all ZVRA earnings summariesZVRA Stock 12 Month Forecast
Average Price Target
$24.50
▲(121.12% Upside)
Technical Analysis
Lexicon Pharmaceuticals
―
Prothena
―
Ocugen
―
Corvus Pharmaceuticals
―
Solid Biosciences
―
Ownership Overview
0.81% Insiders
9.95% Mutual Funds
0.03% Other Institutional Investors
79.07% Public Companies and Individual Investors